USPTO serial 79292735
ALZPROTECT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 10, 2021
- Examiner
- ANKRAH, NAAKWAMA S
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ALZPROTECT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,046*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John J. O'Malley
John J. O'Malley Volpe Koenig30 South 17th StreetSuite 1800Philadelphia, PA 19103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic preparations for science or research; diagnostic products for science or research; diagnostic reagents for science or research; active chemical ingredients for use in the manufacture of medicines for Alzheimer's disease; active synthetic organic chemical products and/or reagents used in the manufacture of medicaments, especially for the treatment of neurodegenerative diseases such as Alzheimer's disease, amyloidopathies, tauopathies and synucleopathies; synthetic organic chemical products and/or reagents used in the manufacture of veterinary products; synthetic organic chemicals for use in industry and science; chemical reagents other than for medical or veterinary use; vitamins for the manufacture of food supplements | ACTIVE | — |
| 005 | Pharmaceutical products for the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease, amyloidopathies, tauopathies and synucleopathies; medicines; active ingredients of medicines for the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease, amyloidopathies, tauopathies and synucleopathies; diagnostic agents for medical use; diagnostic preparations for medical use; diagnostic biomarker reagents for medical purposes; diagnostic agents for veterinary use; diagnostic preparations for veterinary use; dietetic foods adapted for medical use; dietetic foodstuffs adapted for veterinary use; food supplements; chemical preparations for medical use namely for the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease, amyloidopathies, tauopathies and synucleopathies ; chemical preparations for pharmaceutical use namely for the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease, amyloidopathies, tauopathies and synucleopathies; medicinal herbs; herbal teas for medicinal purposes; food supplements consisting of vitamins; vitamin supplements; vitamin preparations; dietetic preparations adapted for medical purposes and food supplements; dietetic food supplements based primarily on vitamins adapted for medical purposes; dietetic food preparations adapted for medical purpose; medicated food supplements; nutritional and food supplements; vitamin and mineral supplements; vitamin preparations; nutritional supplements consisting primarily of vitamins or minerals for medical use; vitamins and minerals; nutraceuticals for use as a dietary supplement for therapeutic use; nutraceutical preparations for use as a dietary supplement for therapeutic or medical use; nutraceutical products used as dietary supplements | ACTIVE | — |
| 042 | Evaluations, estimates and research in the scientific and technological fields of therapeutic treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease, amyloidopathies, tauopathies and synucleopathies, provided by engineers or researchers; research and product development in the field of diagnostic products and preparations; research and development of pharmaceutical products and preparations; research and development of medicines; medicine discovery services in the nature of development of pharmaceutical preparations; engineering services in the form of technical evaluations concerning design for quality control concerning design of new pharmaceutical products; scientific research; technical research in the field of pharmaceutical studies; research and development of new products for third parties; conducting of technical project studies namely, technological research in the field of medical instruments | ACTIVE | — |
| 044 | Medical diagnostic services for diagnostic and treatment purposes provided by medical laboratories; medical services; hospital services; alternative medicine services; providing nutrition information | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ALZPROTECT
- Other trademarks owned by ALZPROTECT
- Other trademarks owned by ALZPROTECT
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ALZPROTECT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 10, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Feb 6, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 18, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 18, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 10, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 10, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 25, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 25, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 23, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| May 5, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 5, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| May 5, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 21, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 20, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 20, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 20, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 13, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 23, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 23, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 5, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 4, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 2, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 8, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 4, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 3, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |